tags

CIRS Group has categorized the cosmetic regulations that have already taken effect or been implemented in major global markets as of July 31, 2026 (inclusive), for your reference.

Illinois signed Chemicals in Cosmetic Products Act into law on July 10, 2026, banning cosmetics with 24 specified intentionally added ingredients starting July 1, 2028.

CIRS Group has compiled and summarized the latest global cosmetic regulatory developments of June 2026.

Global CosIng, a leading cosmetic ingredient regulatory data platform developed by CIRS Group, today announced the official launch of Global CosIng 2.0!

This article compiles and summarizes the latest developments in cosmetics regulations worldwide as of May 2026.

In a landmark move for the U.S. sunscreen industry, the FDA has approved Bemotrizinol (Bis-ethylhexyloxyphenol methoxyphenyl triazine) for inclusion in the over-the-counter (OTC) sunscreen monograph as a permitted active ingredient. Announced on June 9, 2026, this is the first new active ingredient added to the monograph in more than two decades, reflecting ongoing efforts to modernize the U.S. sunscreen regulatory system. The final order takes effect on August 9, 2026.

CIRS Group has compiled and summarized the latest global cosmetics regulatory developments in April 2026, covering industry news, new regulations, policy adjustments, and regulatory trends, helping companies stay compliant and fully informed of the evolving global cosmetics regulatory landscape.

On April 15, 2026, the Minnesota Pollution Control Agency (MPCA) announced a second extension of the initial PFAS products reporting deadline, moving it from July 1, 2026 to September 15, 2026. Upon completion of the initial report, subsequent annual reports are due each February 1. Manufacturers unable to meet the deadline may apply for a single 90-day extension (to December 14, 2026).

Globally, the regulatory landscape for exosome cosmetics exhibits significant variability. This article systematically reviews the management measures, regulations, and ethical standards concerning exosome cosmetics in various countries/regions, including the United States, the European Union, Japan, South Korea, Taiwan, and mainland China. It explores the context of compliance and prohibitions, as well as their impact on industry development, providing comprehensive global regulatory compliance guidance for cosmetic companies.

On March 11, 2026, the U.S. Food and Drug Administration (FDA) launched a new unified platform for analyzing adverse event reports, known as the FDA Adverse Event Monitoring System (AEMS). This initiative marks a significant milestone in the agency’s mission to modernize and enhance transparency regarding the safety of regulated products.On March 11, 2026, the U.S. Food and Drug Administration (FDA) launched a new unified platform for analyzing adverse event reports, known as the FDA Adverse Event Monitoring System (AEMS). This initiative marks a significant milestone in the agency’s mission to modernize and enhance transparency regarding the safety of regulated products.